On April 15, 2026, Health and Human Services Secretary Robert F. Kennedy Jr. announced that the FDA will convene a Pharmacy Compounding Advisory Committee meeting in July 2026 to review whether roughly a dozen peptide substances should be moved onto the 503A Bulks List — the register of drug ingredients compounding pharmacies are allowed to prepare on an individual-prescription basis. The announcement triggered an immediate market reaction: Hims & Hers Health (NYSE: HIMS) closed April 16 at $26.98, up 11.07% on volume of 74.6 million shares (111% above three-month average), after climbing another 6.88% premarket. Over two trading days the stock rose 25% — a meaningful recovery after the company's mid-2025 compounded-GLP-1 setback.

Why It Matters

The peptide review lands directly in the male-sexual-health and longevity-wellness markets that Hims has been building out. PT-141 is a next-generation sexual-desire drug already available through some telehealth platforms as a compounded product; if it clears the 503A list, it becomes broadly prescribable and Hims' existing subscriber base (millions of ED and hair-loss patients) is the obvious distribution channel. It's also a political pivot: after 2025's FDA enforcement against compounded tirzepatide cratered Hims' stock, the Kennedy HHS has chosen to broaden rather than narrow compounding access — a policy posture that directly benefits sexual-health telehealth if sustained.

The 503A reclassification matters because peptides in FDA "Category 2" restricted status can't be compounded for patients; moving them to the bulks list would open the door to personalized-dose preparations by licensed compounding pharmacies. Twelve peptides are in the initial tranche; seven additional peptides are queued for a follow-up review. Kennedy's announcement, foreshadowed on his Joe Rogan appearance in late March, signals the first substantive reversal of 2023 FDA restrictions that effectively cleared peptide shelves.

For Hims & Hers specifically, the policy shift is doubly relevant. The company acquired a California peptide manufacturing facility in early 2025, giving it direct capacity to compound GLP-1 alternatives and sexual-health-adjacent peptides (PT-141/bremelanotide, which markets to sexual arousal; BPC-157 for recovery; CJC-1295/Ipamorelin for growth hormone axis). A Bank of America analyst raised the HIMS price target from $21 to $25 citing the dual opportunity: converting GLP-1 compounding capacity to peptide production and a broader catalog of personalized peptide therapies for the telehealth platform.

The broader telehealth-compounding ecosystem — including Ro, Lemonaid, Eden, and peptide-focused upstarts — also benefits. Compounding pharmacies that maintained peptide practices in regulatory gray zones can now plan for a clearer legal footing by July. The advisory committee meeting won't guarantee approval; 503A Bulks List additions require a positive committee recommendation followed by FDA rulemaking. But the signaling alone has reshaped trading in the sector.

Sources

Update — 2026-04-19

Initial entry — story first created.